🇺🇸 FDA
Patent

US 9139834

RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesis

granted A61PA61P27/00A61P27/02

Quick answer

US patent 9139834 (RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesis) held by Arrowhead Research Corporation expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Research Corporation
Grant date
Tue Sep 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P27/00, A61P27/02, A61P35/00